O-RAN Alliance Releases First Software Code
Today, the O-RAN Alliance, working with the Linux Foundation, announced the O-RAN Software Community's first software code release, “Amber”.
The goal of the O-RAN Software Community is to advance opening the Radio Access Network (RAN) with a focus on the open interfaces, followed by implementations that leverage new capabilities enabled by the O-RAN specifications.
The Amber release includes initial contributions across 11 software projects. Key highlights include:
- The demonstration of the Operation and Maintenance O1 interface, including multi-vendor radio support.
- The initial release of the O-RAN unique Near Real-Time RAN Intelligent Controller. The Near-RT RIC aims at increasing network performance. It utilizes closed loop (~10ms) measurements to optimize load, energy consumption or other parameters across multiple radios. The O-RAN solution benefits from open access to local RAN data and leverages the O-RAN open architecture, including the E2 and O1 interfaces.
- 3 initial Near-RT RIC microservices (X-APPs) on network admission control, network KPI monitoring and KPI measurement.
- An initial RAN protocol stack from 4G LTE with extendable framework towards 5G standalone mode that leverages the multi-vendor O-RAN architecture with the open fronthaul interface and the F1 interface.
The Amber Release is available at the O-RAN Software Community wiki pages.
The O-RAN Software Community plans to continue rapid development of O-RAN compliant software, following the Linux Foundation 6 months release cycle.
“The first release of the O-RAN Software Community exemplifies the progress we've made as an industry, and AT&T is proud to be a member and active contributor of this effort," said Andre Fuetsch, Chairman of the O-RAN Alliance, Executive Vice President and Chief Technology Officer of AT&T. “Together, we’re driving forward open networking, software and virtualization in global wireless networks, which is critical as we shift to a 5G world.”
"We are really pleased to deliver the first release of the O-RAN Software Community with key elements in both repositories in such a short period of time," said Chih-Lin I, Co-chair of O-RAN Technical Steering Committee (TSC), Chief Scientist of China Mobile. "The Amber Release provides a good framework for the non-realtime RIC and the near-realtime RIC under Apache 2.0, as well as the O-CU and the O-DU under the FRAND-based O-RAN Software License. It demonstrates the value of close alignment between the specification work and the corresponding open source software development.”
“The TOC is proud of all the contributors who have worked hard to bring together the first release of software for an open and intelligent RAN in such a short time,” said John Murray, co-chair of the O-RAN Software Community Technical Oversight Committee and AVP advanced technologies, AT&T. “It is an exciting and evolving domain that is at the front of technology changing our world. The first release is the start of the project and we expect the contributions and functionality to continue as we grow the community of contributors and deliver additional releases in the future.”
“At Nokia we are strong proponents of O-RAN’s core principles of intelligence and openness and believe it will motivate collaboration and drive innovative new services in the industry,” said Michael Clever, Head of Cloud RAN Solutions at Nokia. “We are pleased to be contributing to the Near-RT RIC software in the O-RAN Amber Release. This and future contributions will help prove out the Near-RT RIC and pave the way for wider adoption.”
“Radisys is a champion of O-RAN Alliance and our open strategy has been a guiding beacon for us to help foster the open RAN ecosystem,” said Neeraj Patel, SVP and GM, MobilityEngine Business Unit, Radisys. “We have been working with the O-RAN Alliance and Linux Foundation to bring an open O-DU and O-CU protocol stack as part of the Amber Release. Radisys will continue to play an active role both as an enabler and integrator to fast track the operationalization and commercialization of a multi-vendor ecosystem for 5G RAN.”
“We are pleased to see the O-RAN Software Community issue its first software release, especially in such a short time since forming the project,” said Arpit Joshipura, general manager, Networking, Edge and IoT, the Linux Foundation. “The speed in which this collaboration came together represents a strong commitment across the open source networking ecosystem towards the harmonization of both open source and open standards, as well as cross-stack integration.”
About O-RAN Alliance and the O-RAN Software Community
The O-RAN Alliance is a world-wide, carrier-led effort with more than 130 member operators, vendors, and research & academic institutions operating in the Radio Access Network industry. Its mission is to drive new levels of openness in the radio access network of next generation wireless systems. Future RANs will be built on a foundation of virtualized network elements, white-box hardware and standardized interoperable interfaces that fully embrace O-RAN’s core principles of intelligence and openness.
For more information please visit www.o-ran.org.
The O-RAN Software Community was jointly created by the O-RAN Alliance and the Linux Foundation in April 2019. Its mission is to provide a software solution to support the implementation of an open and intelligent Radio Access Network (RAN), compliant with the O-RAN Alliance specifications.
For more information please visit www.o-ran-sc.org.
About the Linux Foundation
Founded in 2000, the Linux Foundation is supported by more than 1,000 members and is the world's leading home for collaboration on open source software, open standards, open data, and open hardware. Linux Foundation's projects are critical to the world's infrastructure including Linux, Kubernetes, Node.js, and more. The Linux Foundation's methodology focuses on leveraging best practices and addressing the needs of contributors, users and solution providers to create sustainable models for open collaboration. For more information please visit us at www.linuxfoundation.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005530/en/
Contact information
Zbynek Dalecky
O-RAN Alliance e.V.
pr@o-ran.org
+420 603 400 524
Jill Lovato
The Linux Foundation
jlovato@linuxfoundation.org
+1 503 703 8268
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma
Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu
Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EET | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer
BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EET | Press release
BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom